ARBITER 6-HALTS. Does it have the power to settle all matters?

Anonymous (1975) Clofibrate and niacin in coronary heart disease. JAMA 231: 360-381.

Alderman, J.D. , Pasternak, R.C. , Sacks, F.M. , Smith, H.S. , Monrad, E.S. and Grossman, W. ( 1989) Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high density lipoprotein cholesterol and the cholesterol to high density lipoprotein ratio. Am J Cardiol 64: 725-729.

Blankenhorn, D.H. , Johnson, R.L. , Nessim, S.A. , Azen, S.P. , Sanmarco, M.E. and Selzer, R.H. ( 1987) The Cholesterol Lowering Atherosclerosis Study (CLAS): design, methods, and baseline results. Control Clin Trials 8: 356-387.

Cannon, C.P. , Giugliano, R.P. , Blazing, M.A. , Harrington, R.A. , Peterson, J.L. , Sisk, C.M. et al. (2008) Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/ simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 156: 826-832.

Cheng, Y. , Liu, F. , Wu, J. , Zhang, Y. , Nilsson, A. and Duan, R.D. ( 2009) Ezetimibe Inhibits Expression of Acid Sphingomyelinase in Liver and Intestine. Lipids [Epub ahead of print].

Cziraky, M.J. , Watson, K.E. and Talbert, R.L. ( 2008) Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. J Manag Care Pharm 14: S3-28.

Farmer, J.A. ( 2009) Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis (the SEAS trial). Curr Atheroscler Rep 11: 82-83.

Fellstrom, B. , Holdaas, H. , Jardine, A.G. , Svensson, M.K. , Gottlow, M. , Schmieder, R.E. et al. (2009) Cardiovascular disease in patients with renal disease: the role of statins. Curr Med Res Opin 25: 271-285.

Garcia-Calvo, M. , Lisnock, J. , Bull, H.G. , Hawes, B.E. , Burnett, D.A. , Braun, M.P. et al. (2005) The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A 102: 8132-8137.

Goldberg, A.C. ( 1998) Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study. Am J Cardiol 82: 35U-38U.

Halleck, M. , Davis, H.R. , Kirschmeier, P. , Levitan, D. , Snyder, R.D. , Treinen, K. et al. (2009) An assessment of the carcinogenic potential of ezetimibe using nonclinical data in a weight-of-evidence approach. Toxicology 258: 116-130.

Helfand, M. , Buckley, D.I. , Freeman, M. , Fu, R. , Rogers, K. , Fleming, C. et al. (2009) Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force. Ann Intern Med 151: 496-507.

Kastelein, J.J. , Akdim, F. , Stroes, E.S. , Zwinderman, A.H. , Bots, M.L. , Stalenhoef, A.F. et al. (2008) Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 358: 1431-1443.

Kastelein, J.J. and Bots, M.L. (2009) Statin Therapy with Ezetimibe or Niacin in High-Risk Patients. N Engl J Med 361: 2180-2183.

Kastelein, J.J. , Sager, P.T. , de, G.E. and Veltri, E. ( 2005) Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. Am Heart J 149: 234-239.

Keenan, J.M. , Fontaine, P.L. , Wenz, J.B. , Myers, S. , Huang, Z.Q. and Ripsin, C.M. ( 1991) Niacin revisited. A randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia. Arch Intern Med 151: 1424-1432.

Lee, J.M. , Robson, M.D. , Yu, L.M. , Shirodaria, C.C. , Cunnington, C. , Kylintireas, I. et al. (2009) Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol 54: 1787-1794.

Maccubbin, D. , Bays, H.E. , Olsson, A.G. , Elinoff, V. , Elis, A. , Mitchel, Y. et al. (2008) Lipid-modifying efficacy and tolerability of extended-release niacin/ laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract 62: 1959-1970.

McKenney, J.M. , McCormick, L.S. , Weiss, S. , Koren, M. , Kafonek, S. and Black, D.M. ( 1998) A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group. Am J Med 104: 137-143.

McNamara, E. and Archer, M.C. ( 2009) Ezetimibe reverses the inhibitory effects of dietary cholesterol on mammary tumorigenesis in rats. Int J Cancer [Epub ahead of print].

Mitka, M. ( 2008) Cholesterol drug controversy continues. JAMA 299: 2266.

Nessim, S.A. , Chin, H.P. , Alaupovic, P. and Blankenhorn, D.H. ( 1983) Combined therapy of niacin, colestipol, and fat-controlled diet in men with coronary bypass. Effect on blood lipids and apolipoproteins . Arteriosclerosis 3: 568-573.

Nissen, S.E. , Tardif, J.C. , Nicholls, S.J. , Revkin, J.H. , Shear, C.L. , Duggan, W.T. et al. (2007) Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 356: 1304-1316.

Paolini, J.F. , Bays, H.E. , Ballantyne, C.M. , Davidson, M. , Pasternak, R. , Maccubbin, D. et al. (2008) Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors. Cardiol Clin 26: 547-560.

Taylor, A.J. , Villines, T.C. , Stanek, E.J. , Devine, P.J. , Griffen, L. , Miller, M. et al. (2009) Extended-Release Niacin or Ezetimibe and Carotid Intima-Media Thickness. N Engl J Med 361: 2113-2122.

Walldius, G. and Wahlberg, G. ( 1985) Effects of nicotinic acid and its derivatives on lipid metabolism and other metabolic factors related to atherosclerosis. Adv Exp Med Biol 183: 281-293.

Windler, E. , Schoffauer, M. and Zyriax, B.C. ( 2007) The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease. Diab Vasc Dis Res 4: 136-142.